Arteriovenous Malformations Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major arteriovenous malformations markets are expected to exhibit a CAGR of 6.1% during 2024-2034.
The arteriovenous malformations market has been comprehensively analyzed in IMARC's new report titled "Arteriovenous Malformations Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Arteriovenous malformations are irregular tangles of blood vessels that directly connect arteries to veins, bypassing the capillary network. This congenital vascular disorder can occur in various parts of the body, including the brain and spinal cord. Arteriovenous malformations are mainly characterized by their potential to disrupt normal blood flow and oxygen exchange, leading to several health complications. The symptoms of the illness can vary widely depending on their location and size. Common neurological signs may include headaches, seizures, weakness, numbness, and even paralysis. In cases where an arteriovenous malformation ruptures, it can cause severe bleeding in the brain, leading to indications, such as sudden and severe headaches, neurological deficits, and loss of consciousness, which can be life-threatening. Diagnosing this ailment often involves a combination of imaging techniques like angiography, MRI (magnetic resonance imaging), and CT (computed tomography) scans. Angiography is particularly useful as it provides detailed visualizations of the abnormal blood vessels' structure and blood flow patterns.
The increasing incidences of numerous associated risk factors, including genetic predisposition, exposure to certain toxins or chemicals, abnormal embryonic development, hormonal changes, trauma, injury, etc., are primarily driving the arteriovenous malformations market. In addition to this, the inflating utilization of minimally invasive procedures, such as endovascular embolization, which involves blocking abnormal blood vessels to restore normal blood flow patterns, is also creating a positive outlook for the market. Moreover, the widespread adoption of physical and neurorehabilitation therapies, since they help in enhancing motor functions, coordination, and overall quality of life for individuals suffering from arteriovenous malformations, is further bolstering the market growth. Apart from this, the rising usage of gene therapy, that involves introducing functional genetic material to rectify or replace mutated genes responsible for the condition, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of efficacious treatments, such as embolization, surgical resection, stereotactic radiosurgery, and pharmacological therapies aimed at managing symptoms and preventing adverse outcomes is also augmenting the market growth. Furthermore, the escalating application of targeted therapies, like anti-angiogenic drugs that work by inhibiting the generation of new blood vessels in the affected area, is expected to drive the arteriovenous malformations market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the arteriovenous malformations market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for arteriovenous malformations and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the arteriovenous malformations market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the arteriovenous malformations market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the arteriovenous malformations market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current arteriovenous malformations marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the arteriovenous malformations market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the arteriovenous malformations market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the arteriovenous malformations market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of arteriovenous malformations across the seven major markets?
What is the number of prevalent cases (2018-2034) of arteriovenous malformations by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of arteriovenous malformations by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with arteriovenous malformations across the seven major markets?
What is the size of the arteriovenous malformations patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of arteriovenous malformations?
What will be the growth rate of patients across the seven major markets?
Arteriovenous Malformations: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for arteriovenous malformations drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the arteriovenous malformations market?
What are the key regulatory events related to the arteriovenous malformations market?
What is the structure of clinical trial landscape by status related to the arteriovenous malformations market?
What is the structure of clinical trial landscape by phase related to the arteriovenous malformations market?
What is the structure of clinical trial landscape by route of administration related to the arteriovenous malformations market?
The arteriovenous malformations market has been comprehensively analyzed in IMARC's new report titled "Arteriovenous Malformations Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Arteriovenous malformations are irregular tangles of blood vessels that directly connect arteries to veins, bypassing the capillary network. This congenital vascular disorder can occur in various parts of the body, including the brain and spinal cord. Arteriovenous malformations are mainly characterized by their potential to disrupt normal blood flow and oxygen exchange, leading to several health complications. The symptoms of the illness can vary widely depending on their location and size. Common neurological signs may include headaches, seizures, weakness, numbness, and even paralysis. In cases where an arteriovenous malformation ruptures, it can cause severe bleeding in the brain, leading to indications, such as sudden and severe headaches, neurological deficits, and loss of consciousness, which can be life-threatening. Diagnosing this ailment often involves a combination of imaging techniques like angiography, MRI (magnetic resonance imaging), and CT (computed tomography) scans. Angiography is particularly useful as it provides detailed visualizations of the abnormal blood vessels' structure and blood flow patterns.
The increasing incidences of numerous associated risk factors, including genetic predisposition, exposure to certain toxins or chemicals, abnormal embryonic development, hormonal changes, trauma, injury, etc., are primarily driving the arteriovenous malformations market. In addition to this, the inflating utilization of minimally invasive procedures, such as endovascular embolization, which involves blocking abnormal blood vessels to restore normal blood flow patterns, is also creating a positive outlook for the market. Moreover, the widespread adoption of physical and neurorehabilitation therapies, since they help in enhancing motor functions, coordination, and overall quality of life for individuals suffering from arteriovenous malformations, is further bolstering the market growth. Apart from this, the rising usage of gene therapy, that involves introducing functional genetic material to rectify or replace mutated genes responsible for the condition, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of efficacious treatments, such as embolization, surgical resection, stereotactic radiosurgery, and pharmacological therapies aimed at managing symptoms and preventing adverse outcomes is also augmenting the market growth. Furthermore, the escalating application of targeted therapies, like anti-angiogenic drugs that work by inhibiting the generation of new blood vessels in the affected area, is expected to drive the arteriovenous malformations market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the arteriovenous malformations market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for arteriovenous malformations and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the arteriovenous malformations market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the arteriovenous malformations market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the arteriovenous malformations market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current arteriovenous malformations marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report
Market Insights
How has the arteriovenous malformations market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the arteriovenous malformations market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the arteriovenous malformations market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of arteriovenous malformations across the seven major markets?
What is the number of prevalent cases (2018-2034) of arteriovenous malformations by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of arteriovenous malformations by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with arteriovenous malformations across the seven major markets?
What is the size of the arteriovenous malformations patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of arteriovenous malformations?
What will be the growth rate of patients across the seven major markets?
Arteriovenous Malformations: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for arteriovenous malformations drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the arteriovenous malformations market?
What are the key regulatory events related to the arteriovenous malformations market?
What is the structure of clinical trial landscape by status related to the arteriovenous malformations market?
What is the structure of clinical trial landscape by phase related to the arteriovenous malformations market?
What is the structure of clinical trial landscape by route of administration related to the arteriovenous malformations market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ARTERIOVENOUS MALFORMATIONS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ARTERIOVENOUS MALFORMATIONS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ARTERIOVENOUS MALFORMATIONS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ARTERIOVENOUS MALFORMATIONS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ARTERIOVENOUS MALFORMATIONS - UNMET NEEDS
10 ARTERIOVENOUS MALFORMATIONS - KEY ENDPOINTS OF TREATMENT
11 ARTERIOVENOUS MALFORMATIONS - MARKETED PRODUCTS
11.1 List of Arteriovenous Malformations Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ARTERIOVENOUS MALFORMATIONS - PIPELINE DRUGS
12.1 List of Arteriovenous Malformations Pipeline Drugs Across the Top 7 Markets
12.1.1 Cobimetinib - Genentech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ARTERIOVENOUS MALFORMATIONS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ARTERIOVENOUS MALFORMATIONS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ARTERIOVENOUS MALFORMATIONS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Arteriovenous Malformations - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Arteriovenous Malformations - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Arteriovenous Malformations - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Arteriovenous Malformations - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Arteriovenous Malformations - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Arteriovenous Malformations - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Arteriovenous Malformations - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Arteriovenous Malformations - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Arteriovenous Malformations - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Arteriovenous Malformations - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Arteriovenous Malformations - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Arteriovenous Malformations - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Arteriovenous Malformations - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Arteriovenous Malformations - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Arteriovenous Malformations - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Arteriovenous Malformations - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Arteriovenous Malformations - Access and Reimbursement Overview
16 ARTERIOVENOUS MALFORMATIONS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ARTERIOVENOUS MALFORMATIONS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ARTERIOVENOUS MALFORMATIONS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ARTERIOVENOUS MALFORMATIONS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ARTERIOVENOUS MALFORMATIONS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ARTERIOVENOUS MALFORMATIONS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ARTERIOVENOUS MALFORMATIONS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ARTERIOVENOUS MALFORMATIONS - UNMET NEEDS
10 ARTERIOVENOUS MALFORMATIONS - KEY ENDPOINTS OF TREATMENT
11 ARTERIOVENOUS MALFORMATIONS - MARKETED PRODUCTS
11.1 List of Arteriovenous Malformations Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ARTERIOVENOUS MALFORMATIONS - PIPELINE DRUGS
12.1 List of Arteriovenous Malformations Pipeline Drugs Across the Top 7 Markets
12.1.1 Cobimetinib - Genentech
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ARTERIOVENOUS MALFORMATIONS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ARTERIOVENOUS MALFORMATIONS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ARTERIOVENOUS MALFORMATIONS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Arteriovenous Malformations - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Arteriovenous Malformations - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Arteriovenous Malformations - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Arteriovenous Malformations - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Arteriovenous Malformations - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Arteriovenous Malformations - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Arteriovenous Malformations - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Arteriovenous Malformations - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Arteriovenous Malformations - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Arteriovenous Malformations - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Arteriovenous Malformations - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Arteriovenous Malformations - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Arteriovenous Malformations - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Arteriovenous Malformations - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Arteriovenous Malformations - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Arteriovenous Malformations - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Arteriovenous Malformations - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Arteriovenous Malformations - Access and Reimbursement Overview
16 ARTERIOVENOUS MALFORMATIONS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ARTERIOVENOUS MALFORMATIONS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ARTERIOVENOUS MALFORMATIONS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
